SBC-115,337   Click here for help

GtoPdb Ligand ID: 11539

Synonyms: SBC-115337
Compound class: Synthetic organic
Comment: SBC-115,337 is an orally bioavailable small molecule from Shifa Biomedical's patent WO2017222953A, in which it is claimed as an inhbitor of the proprotein convertase subtilisin kexin type 9 (PCSK9)/low density lipoprotein receptor (LDLR) protein-protein interaction as a novel mechanism to control dyslipidemia [1-2]. This compound offers a first-in-class oral lead for hypercholesterolemia and more generally cardiovascular disease. In the absence of formal name-to-structure disclosure, we can speculate that SBC-115,337 may be P-21 as discussed in Shifa's press release of May 2021 (link here), based on SBC-115,337 being taken into in vivo testing. Shifa are partnering with Xontogeny to progress P-21 to clinical trial.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

SBC-115,337 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 97.37
Molecular weight 473.14
XLogP 5.16
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=C(c1ccc(cc1)NC(=O)c1oc2c(c1)cccc2)Nc1ccc(cc1)c1oc2c(n1)cccc2
Isomeric SMILES O=C(c1ccc(cc1)NC(=O)c1oc2c(c1)cccc2)Nc1ccc(cc1)c1oc2c(n1)cccc2
InChI InChI=1S/C29H19N3O4/c33-27(30-21-15-11-19(12-16-21)29-32-23-6-2-4-8-25(23)36-29)18-9-13-22(14-10-18)31-28(34)26-17-20-5-1-3-7-24(20)35-26/h1-17H,(H,30,33)(H,31,34)
InChI Key ALQIZRCPSILFNQ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Abdel-Meguid SS, Elshourbagy NA, Meyers HV, Mousa SA. (2017)
Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases.
Patent number: WO2017222953A1. Assignee: Shifa Biomedical Corporation. Priority date: 21/06/2016. Publication date: 28/12/2017.
2. Xu S, Luo S, Zhu Z, Xu J. (2019)
Small molecules as inhibitors of PCSK9: Current status and future challenges.
Eur J Med Chem, 162: 212-233. [PMID:30448414]